Astrazeneca (AZN) Gross Margin (2009 - 2026)
Astrazeneca (AZN) recorded quarterly Gross Margin of 16376.62% in Q1 2026, down 92.07% quarter-over-quarter from 206416.67% in Q4 2025, and up 104284.0% on a YoY basis from N/an in Q1 2025.
Astrazeneca (AZN) Gross Margin (2009 - 2026) Analysis & Trends
Astrazeneca's Gross Margin history runs 18 years deep, the most recent figure standing at 16376.62% for Q1 2026.
- In Q1 2026, Gross Margin rose 104284.0% year-over-year to 16376.62%; the TTM figure through Mar 2026 stood at 48400.98% (up 4370014.0% YoY), while the FY2025 annual figure was 81.9%, down 467065.0% from the prior year.
- Gross Margin was 16376.62% for Q1 2026 at Astrazeneca, down from 206416.67% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 268875.0% in Q2 2024 to a low of 1492.76% in Q4 2024.
- Historically, Gross Margin has averaged 66775.58% across 5 years, with a median of 16376.62% in 2026.
- The sharpest annual moves came in 2023 and 2024: Gross Margin plunged 25420052 bps in 2023, then jumped 26397552 bps in 2024.
- A 5-year view of Gross Margin shows it stood at 5257.59% in 2022, then slumped by 33 bps to 3507.58% in 2023, then plunged by 57 bps to 1492.76% in 2024, then jumped by 13728 bps to 206416.67% in 2025, then plunged by 92 bps to 16376.62% in 2026.
- The last three Gross Margin figures came in at 16376.62% (Q1 2026), 206416.67% (Q4 2025), and 112636.36% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 70.22% |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | 16,376.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,376.62% |
| Dec 31, 2025 | 206,416.67% |
| Sep 30, 2025 | 112,636.36% |
| Jun 30, 2025 | 149,800.00% |
| Mar 31, 2025 | 15,333.78% |
| Dec 31, 2024 | 1,492.76% |
| Sep 30, 2024 | 17,769.49% |
| Jun 30, 2024 | 268,875.00% |
| Mar 31, 2024 | 23,246.67% |
| Dec 31, 2023 | 3,507.58% |
| Sep 30, 2023 | 9,687.63% |
| Jun 30, 2023 | 4,899.48% |
| Mar 31, 2023 | 33,237.04% |
| Dec 31, 2022 | 5,257.59% |
| Sep 30, 2022 | 4,494.38% |
| Jun 30, 2022 | 259,100.00% |
| Mar 31, 2022 | 3,053.88% |
| Dec 31, 2021 | 1,439.77% |
| Sep 30, 2021 | 4,887.20% |
| Jun 30, 2021 | 3,445.14% |